Clinical Trial Update: A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of the meningococcal B vaccine RLP2086 in adolescents has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease

Drugs mentioned

• rLP2086 vaccine

Snippet

Sponsor: Pfizer | Conditions: Meningitis, Meningococcal | Phase 2 | Status: COMPLETED | Results posted: 2015-04-14